Our top pick for
PartnerRe Ltd is an insurance-reinsurance business based in the US. PartnerRe shares (PRE-PH) are listed on the NYSE and all prices are listed in US Dollars. PartnerRe employs 1,008 staff and has a trailing 12-month revenue of around USD$7.2 billion.
|Latest market close||USD$25.7|
|52-week range||USD$16.6696 - USD$26.5412|
|50-day moving average||USD$25.7019|
|200-day moving average||USD$25.9548|
|Wall St. target price||N/A|
|Dividend yield||USD$1.81 (7.06%)|
|Earnings per share (TTM)||USD$9.665|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||0.12%|
|1 month (2020-12-15)||-0.11%|
|3 months (2020-10-15)||-1.76%|
|6 months (2020-07-15)||-1.12%|
|1 year (2020-01-15)||-5.86%|
|2 years (2019-01-15)||-2.84%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
Valuing PartnerRe stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PartnerRe's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PartnerRe's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, PartnerRe shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
PartnerRe's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.1 billion.
The EBITDA is a measure of a PartnerRe's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$7.2 billion|
|Gross profit TTM||USD$1.5 billion|
|Return on assets TTM||-0.11%|
|Return on equity TTM||-0.82%|
|Market capitalisation||USD$2.6 billion|
TTM: trailing 12 months
We're not expecting PartnerRe to pay a dividend over the next 12 months.
Over the last 12 months, PartnerRe's shares have ranged in value from as little as $16.6696 up to $26.5412. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while PartnerRe's is -0.022. This would suggest that PartnerRe's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, PartnerRe has bucked the trend.
PartnerRe Ltd., through its subsidiaries, provides reinsurance in Europe, North America, Asia, Australia, New Zealand, Latin America, the Caribbean, and Africa. It operates through three segments: Property & Casualty, Specialty, and Life and Health. The company reinsures various risks, including agriculture, aviation/space, casualty, catastrophe, energy, engineering, financial risks, marine, motor, multiline, and property, as well as mortality, morbidity, longevity, accident, and health products. It also reinsures alternative risk products consisting of weather and credit protection insurance to financial, industrial, and service companies. The company offers its products through brokers and direct relationships with insurance companies. PartnerRe Ltd. was founded in 1993 and is based in Pembroke, Bermuda. PartnerRe Ltd. is a subsidiary of EXOR Nederland N.V.
Everything we know about the Bakkt Holdings IPO, plus information on how to buy in.
Everything we know about the Dream Finders Homes Inc IPO, plus information on how to buy in.
Everything we know about the Q BioMed Inc IPO, plus information on how to buy in.
Everything we know about the Faraday Future IPO, plus information on how to buy in.
Everything we know about the TELUS International Inc IPO, plus information on how to buy in.
Everything we know about the Interior Logic Group Holdings LLC IPO, plus information on how to buy in.
Everything we know about the Evaxion Biotech IPO, plus information on how to buy in.
Everything we know about the ON24 Inc IPO, plus information on how to buy in.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.